KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $37.7 million.

  • Sarepta Therapeutics' Depreciation & Amortization (CF) rose 88.15% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.7 million, marking a year-over-year increase of 28.68%. This contributed to the annual value of $37.7 million for FY2024, which is 15.03% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Depreciation & Amortization (CF) of $37.7 million as of FY2024, which was down 15.03% from $44.4 million recorded in FY2023.
  • Over the past 5 years, Sarepta Therapeutics' Depreciation & Amortization (CF) peaked at $44.4 million during FY2023, and registered a low of $26.9 million during FY2020.
  • In the last 3 years, Sarepta Therapeutics' Depreciation & Amortization (CF) had a median value of $41.9 million in 2022 and averaged $41.3 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 41.27% in 2021, then dropped by 15.03% in 2024.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Depreciation & Amortization (CF) stood at $26.9 million in 2020, then surged by 41.27% to $38.0 million in 2021, then increased by 10.12% to $41.9 million in 2022, then climbed by 6.05% to $44.4 million in 2023, then declined by 15.03% to $37.7 million in 2024.